key: cord-0884897-oiczz6gc
authors: Bansal, Naveen; Raturi, Manish; Bansal, Yashik
title: COVID-19 Convalescent plasma use in the oncology and geriatric patients: Ethical aspects in transfusion medicine
date: 2021-12-11
journal: Transfus Clin Biol
DOI: 10.1016/j.tracli.2021.12.001
sha: bbe3ed5de0852780d4bb7661733c8840b6176208
doc_id: 884897
cord_uid: oiczz6gc

nan

Journal Pre-proof Dear Sir,

We read with great interest the article entitled "Transfusion at the border of the "intention-totreat", in the very aged person and palliative care: A debate" by Garraud. O [1] . We wish to share our thoughts related to this article. As discussed in the article [1] , the ethical issues regarding blood transfusion in palliative care and geriatrics are mainly with the red blood cell and platelet transfusion and not with plasma transfusion because the latter is rarely prescribed for palliative care. However, the coronavirus disease (COVID-19) pandemic has changed this scenario, as COVID-19 convalescent plasma (CCP) has emerged as an important therapeutic option, especially in immunodeficient patients including oncology patients [2] . Herein, we discuss the important ethical aspects related to the use of CCP in the management of oncology and geriatric patients.

Apart from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibodies, CCP also contains non-neutralizing antibodies that can assist in the entry of the virus into macrophages [3] . The virus multiplies rapidly in the macrophages, thereby, producing a proinflammatory condition, which subsequently can result in worsening of the cytokine storm [3] .

Maro-Rillo et al. reported a case of convalescent plasma transfusion induced acute respiratory distress syndrome in a patient with Ebola virus disease [4] . Moreover, elderly patients have an age-related mild inflammatory condition called "inflame-ageing" and are more susceptible to developing a cytokine storm after COVID-19 infection [5] . Before a decision of transfusing CCP is made, in an elderly patient, these aspects must be kept in mind.

The majority of oncology patients belong to the geriatric age group. Additionally, they generally have an immunocompromised state, and consequently, with defective viral clearance, they are more prone to develop chronic prolonged SARS-CoV-2 infection [6] . The current evidence that CCP administration in immunocompromised patients could accelerate the generation of SARS-CoV-2 variants [7] should also be kept in mind before planning a CCP transfusion in such a cohort of patients.

Page 3 of 4 J o u r n a l P r e -p r o o f As per FDA emergency use authorization, only high titer CCP can be used in the patients that too only in the early stages of COVID-19, except for immunocompromised patients, in which case CCP could be, transfused at any stage of COVID-19 [8] . In India, in many instances, CCP was being administered either without doing any antibody titration and/or late in the course of infection [9] . Eventually, due to the indiscriminate use of CCP, it proved to be non-efficacious and ultimately led to the scrapping of CCP from the management protocols for COVID-19 in India [9] . Therefore, as suggested by Garraud O in the article [1] , a careful risk-benefit analysis, should be undertaken before administering CCP in any patient. Rather, a scoring system may also be used for this purpose [10] .

Ethical issues related to plasma donors should also be kept in mind. There have been reports of donors being offered financial incentives for the donation of CCP [11, 12] . Blood centres should ensure that the CCP donors are non-remunerated voluntary donors. At the same time, the process of informed consent and donor confidentiality also merits consideration [13] . Finally, ethical considerations must be the front line of the transfusion debate, especially in the matter of the very aged person or in palliative care [14] . The motto should be the best possible patient outcome and based on the underlying principle of justice with a pure intent to treat.

Transfusion at the border of the "intention-to-treat", in the very aged person and in palliative care: A debate

A look-back at convalescent plasma to treat COVID-19

Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice

Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease

Source of Chronic Inflammation in Aging

Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with

COVID-19 convalescent plasma as long-term therapy in immunodeficient patients

Covid-19 convalescent plasma therapy: Analyzing the factors that led to its failure in India

A novel scoring system for selecting the target patients of COVID-19 convalescent plasma therapy: A hypothesis

Is plasma donation ethics abused

poorest-americans-are-selling-their-blood-the-us-is-in-serious-trouble

Reviewing the Ethical Concerns of the Convalescent Plasma Therapy in COVID-19

Principles of Clinical Ethics and Their Application to Practice